Biomea Fusion (BMEA) Corporate presentation summary

Transforming diabetes and obesity with novel oral medicines

• Advancing two differentiated metabolic programs: icovamenib (menin inhibitor) and BMF-650 (oral GLP-1 receptor agonist).

• Icovamenib aims to restore beta-cell mass and insulin production in both type 1 and type 2 diabetes, addressing a critical unmet need.

• BMF-650 is designed for improved tolerability and scalable weight reduction in obesity, targeting high dropout rates seen with current GLP-1 therapies.

• Funded through key clinical readouts for both programs into Q1 2027.

Clinical pipeline and milestones

• Icovamenib is in Phase II for type 1 and type 2 diabetes, with key 26-week data expected in Q4 2026.

• BMF-650 is in Phase I for obesity, with 28-day weight reduction data anticipated in Q2 2026.

• Full worldwide rights retained across all programs.

Disease landscape and unmet needs

• Over 38 million people in the US have diabetes, with 1 in 3 requiring insulin; current therapies do not restore beta-cell function.

• Obesity affects over 100 million US adults, with high discontinuation rates for GLP-1 therapies due to side effects.

• Both diabetes and obesity are associated with significant morbidity, mortality, and healthcare costs.